Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
HUTCHMED DRC is a drug manufacturers-specialty & generic business based in the US. HUTCHMED DRC shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. HUTCHMED DRC employs 2,110 staff and has a trailing 12-month revenue of around $400.8 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $9.05 |
|---|---|
| 52-week range | $8.37 - $37.00 |
| 50-day moving average | $12.66 |
| 200-day moving average | $18.54 |
| Wall St. target price | $29.31 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.23 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.05 from 2022-09-27
| 1 week (2022-09-21) | -4.74% |
|---|---|
| 1 month (2022-08-26) | -27.07% |
| 3 months (2022-06-28) | -31.95% |
| 6 months (2022-03-28) | -51.29% |
| 1 year (2021-09-28) | -75.11% |
|---|---|
| 2 years (2020-09-28) | -72.07% |
| 3 years (2019-09-27) | 17.97 |
| 5 years (2017-09-28) | 27.24 |
| Revenue TTM | $400.8 million |
|---|---|
| Gross profit TTM | $-201,192,000 |
| Return on assets TTM | -19.32% |
| Return on equity TTM | -24.72% |
| Profit margin | -63.65% |
| Book value | $4.74 |
| Market capitalisation | $1.6 billion |
TTM: trailing 12 months
We're not expecting HUTCHMED DRC to pay a dividend over the next 12 months.
HUTCHMED DRC's shares were split on 29 May 2019.
Over the last 12 months, HUTCHMED DRC's shares have ranged in value from as little as $8.37 up to $37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HUTCHMED DRC's is 0.4991. This would suggest that HUTCHMED DRC's shares are less volatile than average (for this exchange).
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.